Tacrolimus is a calcineurin inhibitor that acts by binding to FK506 binding protein (FKBP), the resulting complex in turn inhibits calcineurin. Tacrolimus is used to prevent organ rejection in organ (including intestine, liver, lung, kidney and pancreas) transplant recipients and is more frequently used than the older calcineurin inhibitor, ciclosporin, due to its superior safety and efficacy (leading to lower rejection rates). It has been used in the management of autoimmune diseases like inflammatory bowel disease too and topical tacrolimus is used to treat severe atopic dermatitis.
↑Gonzalez-Lama, Y; Gisbert, JP; Mate, J (October 2006). "The role of tacrolimus in inflammatory bowel disease: a systematic review.". Digestive Diseases and Sciences51 (10): 1833–40. PMID16964541. doi:10.1007/s10620-006-9209-y.
↑Brayfield, A, ed. (13 January 2014). "Tacrolimus". Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. Retrieved 19 November 2014.